[ad_1]
– New Commitment from Bill & Melinda Gates Foundation Supports Development of Vir’s Novel “Vaccine Antibody” Technology as Another Important Step in Fighting Global Infectious Diseases –
SAN FRANCISCO, Jan. 13, 2022 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq:for) today announced the expansion of its partnership with the Bill & Melinda Gates Foundation to include advances in innovative platform technologies for the development of broadly neutralizing antibodies designed to provide “vaccine” for the treatment of HIV and the prevention of malaria effect”. This novel project combines Vir’s extensive immunology and virology expertise with the Gates Foundation’s longstanding leadership in global health to address two of the world’s most challenging infectious diseases.
“Vir’s partnership with the Bill & Melinda Gates Foundation has been an important part of our company’s history, starting with our T-cell vaccine programs against HIV and tuberculosis. This expansion of the collaboration to a second platform technology supports Our shared goal of developing innovative solutions for the prevention and treatment of infectious diseases worldwide. We look forward to applying lessons learned to date on COVID-19, chronic hepatitis B virus infection and influenza to advance our efforts to treat HIV and prevent malaria hard work,” said Dr. George Scangos, CEO of Vir Biotechnology.
The new program includes a clinical proof-of-concept trial designed to assess the potential impact of broadly neutralizing antibodies designed to inhibit the replication and spread of the virus in HIV-infected individuals, as well as their ability to produce vaccine-like effects applicable to… .
The full story is available on Benzinga.com
[ad_2]
Source link
